GeneDx Holdings Corp. (NASDAQ:WGS) Stock Has Consensus Target Price of $90.86

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $90.14.

A number of brokerages have recently issued reports on WGS. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 9th. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research report on Monday, November 2nd. TD Cowen reaffirmed a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Canaccord Genuity Group boosted their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th.

Insiders Place Their Bets

In related news, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the sale, the chief executive officer owned 115,476 shares of the company’s stock, valued at $11,271,612.36. This trade represents a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,206 shares of company stock worth $1,808,056 over the last quarter. Company insiders own 25.17% of the company’s stock.

Institutional Investors Weigh In On GeneDx

Large investors have recently modified their holdings of the stock. William Blair Investment Management LLC grew its holdings in GeneDx by 11.4% during the third quarter. William Blair Investment Management LLC now owns 1,560,247 shares of the company’s stock valued at $112,806,000 after purchasing an additional 159,594 shares during the period. Russell Investments Group Ltd. raised its stake in shares of GeneDx by 271.7% in the third quarter. Russell Investments Group Ltd. now owns 44,167 shares of the company’s stock valued at $3,193,000 after buying an additional 32,286 shares during the period. Calamos Advisors LLC bought a new stake in shares of GeneDx in the third quarter valued at $225,000. Moody Aldrich Partners LLC lifted its position in shares of GeneDx by 131.9% during the 3rd quarter. Moody Aldrich Partners LLC now owns 36,064 shares of the company’s stock valued at $2,607,000 after buying an additional 20,511 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its position in shares of GeneDx by 851.4% during the 3rd quarter. Sterling Capital Management LLC now owns 666 shares of the company’s stock valued at $48,000 after buying an additional 596 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Stock Up 0.5%

Shares of GeneDx stock opened at $55.12 on Thursday. The stock’s 50-day moving average is $75.23 and its 200 day moving average is $70.68. GeneDx has a one year low of $32.21 and a one year high of $170.87. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -14.58 and a beta of 2.00. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.16 and a quick ratio of 3.06.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.21. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. The firm had revenue of $123.10 million for the quarter, compared to analyst estimates of $122.93 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. Equities research analysts anticipate that GeneDx will post -0.41 EPS for the current year.

Top GeneDx Stories

These are some of the WGS stories that stood out recently:

• Neutral Sentiment: GeneDx said it will participate in upcoming investor conferences; the announcement did not include new financial or operating guidance. Investor conference announcement
• Negative Sentiment: Third-quarter exome and genome results rose 25%, below the company’s previously stated growth expectation of at least 29.2%. GeneDx lowered its 2026 growth target to at least 28%, raising concerns about testing-volume momentum. Article on GeneDx’s testing growth
• Negative Sentiment: The fourth-quarter outlook reportedly missed consensus, adding to concerns about near-term growth. Full-year revenue guidance of $475 million–$490 million spans the $481.1 million analyst estimate, but the range does not signal a clear upside revision. Q4 outlook article

About GeneDx

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.